v3.26.1
Investments accounted for using the equity method (Tables)
12 Months Ended
Dec. 31, 2025
Investments accounted for using the equity method  
Summary of development of the entity's equity method investment

The following table summarizes the development of the investments in associates during year 2025:

​

​

​

​

​

​

​

​

​

Centauri

​

​

​

​

​

​

Therapeutics

​

Insignificant 

​

​

in k€

  ​ ​ ​

Ltd

  ​ ​ ​

investments

  ​ ​ ​

Total

Balance at January 1, 2025

​

1,264

​

874

​

2,138

Investment

​

3,576

​

—

​

3,576

Share of profit/(loss) in associate

​

(634)

​

(451)

​

(1,085)

Impairment

​

—

​

—

​

—

Dividends earned, Divestment or Reclassification

 

—

​

—

​

—

Balance at December 31, 2025

 

4,206

​

423

​

4,629

​

The following table provides an overview of the development of the investments in 2024:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

​

  ​ ​ ​

Centauri

  ​ ​ ​

​

​

Quantro

​

Topas

​

​

  ​ ​ ​

  ​ ​ ​

​

​

Autobahn

​

Therapeutics

​

EIR

​

Therapeutics

​

Therapeutics

​

Insignificant

​

​

in k€

  ​ ​ ​

Labs LLC

  ​ ​ ​

Ltd.

  ​ ​ ​

Biotherapies

​

GmbH

  ​ ​ ​

GmbH

  ​ ​ ​

 investments

  ​ ​ ​

Total

Balance at January 1, 2024

​

—

​

2,179

​

—

​

892

​

—

​

—

 

3,071

Investment

​

1,378

​

—

​

1,022

​

—

​

977

​

2

​

3,379

Share of profit/(loss) in associate

 

(1,378)

​

(916)

​

(149)

​

(892)

​

(977)

​

—

​

(4,312)

Impairment

 

—

​

—

​

—

​

—

​

—

​

—

​

—

Dividends earned, Divestment or Reclassification

​

—

​

—

​

—

​

—

​

—

​

—

 

—

Balance at December 31, 2024

​

—

​

1,264

​

873

​

—

​

—

​

2

 

2,138

Schedule of financial information of significant investments

Further financial information on the significant investments accounted for using the equity method is presented below:

​

2025

​

​

​

​

​

​

Centauri

​

​

Therapeutics

in k€

  ​ ​ ​

Ltd

Current assets

 

14,127

Non-current assets

 

239

Current liabilities

 

233

Non-current liabilities

 

—

Revenues from Jan 1 to Dec 31

​

4,837

Net income (loss) Jan 1 to Dec 31

 

(3,915)

​

2024

​

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

  ​ ​ ​

​

​

​

​

​

​

​

​

​

​

Centauri

​

Dark Blue

​

​

​

Quantro

​

Topas

​

​

Therapeutics

​

Therapeutics

​

EIR

​

Therapeutics

​

Therapeutics

in k€

  ​ ​ ​

Ltd.

​

Ltd.

​

Biotherapies

  ​ ​ ​

GmbH

  ​ ​ ​

GmbH

Current assets

​

383

​

291

​

634

​

1,121

​

7,560

Non-current assets

 

299

​

9,047

​

1,752

 

549

 

972

Current liabilities

 

245

​

981

​

187

 

2,072

 

548

Non-current liabilities

 

—

​

—

​

2

 

4,325

 

—

Revenues from Jan 1 to Dec 31

​

1

​

—

​

—

​

1,294

​

—

Net income (loss) Jan 1 to Dec 31

 

(4,483)

​

(3,115)

​

(167)

 

(3,974)

 

(9,418)

​